參考文獻(xiàn)/References:
[1] YOSHIDA G J.Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways[J]. J Exp Clin Cancer Res,2020,39(1): 112.
[2] KURO O M. The Klotho proteins in health and disease[J]. Nat Rev Nephrol, 2019,15(1): 27-44.
[3] FANG D, ZHANG C F,XU P,et al. S100A16 promotes metastasis and progression of pancreatic cancer through FGF19-mediated AKT and ERK1/2 pathways[J]. Cell Biology and Toxicology, 2021,37(4):555-571.
[4] HOSHI T, MIYANO S W,WATANABE H,et al. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades[J]. Biochem Biophys Res Commun, 2019,513(1): 1-7.
[5] HU L L,CONG L X.Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer[J]. Oncol Rep, 2015,34(5):2683-2691.
[6] WAG D Y,ZHANG J J,LI Z J,et al. Upregulation of fibroblast growth factor 19 is associated with the initiation of colorectal adenoma[J]. Dig Dis, 2019,37(3): 214-225.
[7] KATOH M, NAKAGAMA H. FGF receptors: cancer biology and therapeutics[J].Medicinal Research Reviews, 2014, 34(2):280-300.
[8] ZHANG X C,KONG M,ZHANG Z,et al. FGF19 genetic amplification as a potential therapeutic target in lung squamous cell carcinomas[J]. Thoracic Cancer, 2017,8(6): 655-665.
[9] KANG H J,HAQ F,SUNG C O,et al. Characterization of hepatocellular carcinoma patients with FGF19 amplification assessed by fluorescence in situ hybridization: a large cohort study[J]. Liver Cancer, 2019,8(1): 12-23.
[10] FENG S,DANKHOVA O,CREIGHTON C J,et al. Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression[J].Cancer Research, 2013,73(8):2551-2562.
[11] AGARWAL S,AFAQ F,BAJPAI P,et al. DCZ0415, a small-molecule inhibitor targeting TRIP13, inhibits EMT and metastasis via inactivation of the FGFR4/STAT3 axis and the Wnt/β-catenin pathway in colorectal cancer[J]. Molecular Oncology, 2022,16(8): 1728-1745.
[12] YE Y W,JIANG D B,LI J J,et al. Silencing of FGFR4 could influence the biological features of gastric cancer cells and its therapeutic value in gastric cancer[J]. Tumor Biology, 2015,37(3): 3185-3195.
[13] TIONG K H,TAN B S,CHOO H L,et al.Fibroblast growth factor receptor 4(FGFR4)and fibroblast growth factor 19(FGF19)autocrine enhance breast cancer cells survival[J]. Oncotarget, 2016,7(36):57633-57650.
[14] GAO L X,LANG L W,ZHAO X D,et al.FGF19 amplification reveals an oncogenic dependency upon autocrine FGF19/FGFR4 signaling in head and neck squamous cell carcinoma[J]. Oncogene, 2018,38(13): 2394-2404.
相似文獻(xiàn)/References:
[1]楊國(guó)華 鄭圣斌 林彩鋒 黃若磊.腫瘤相關(guān)成纖維細(xì)胞經(jīng)FGF19/FGFR4信號(hào)軸調(diào)控結(jié)腸癌細(xì)胞生長(zhǎng)的實(shí)驗(yàn)研究[J].福建醫(yī)藥雜志,2020,42(04):136.
YANG Guohua,ZHENG Shengbin,LIN Caifeng,et al.Experimental study on CAF regulating the growth of colorectal cancer through the signal axis of fibroblast growth factor 4/fibroblast growth factor 19[J].FUJIAN MEDICAL JOURNAL,2020,42(05):136.
[2]陳惠珍,吳芙蓉,陳穎嬌.ERAS理念指導(dǎo)下的護(hù)理干預(yù)在老年單孔加一孔腹腔鏡結(jié)腸癌根治術(shù)圍手術(shù)期中的應(yīng)用[J].福建醫(yī)藥雜志,2024,46(02):150.[doi:10.20148/j.fmj.2024.02.044]